Sorrento Therapeutics, Inc. Stock
Stocks
SRNE
US83587F2020
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
OTC Markets
2026-10-16
|
5-day change | 1st Jan Change | ||
| 0.000500 USD | 0.00% |
|
-37.50% | -80.77% |
| 03-17 | Semnur Pharmaceuticals, Inc. Announces CEO Changes, Effective March 13, 2026 | CI |
| 03-17 | Semnur Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 67.15M 59.69M 55.32M 50.33M 94.98M 6.37B 96.51M 665M 261M 3.33B 252M 247M 10.6B | P/E 2021 |
-3.2x | P/E 2022 | -0.65x |
|---|---|---|---|---|---|
| Enterprise Value | 152M 135M 125M 114M 215M 14.4B 218M 1.5B 589M 7.51B 569M 557M 23.95B | EV / Sales 2021 |
29.1x | EV / Sales 2022 | 7.89x |
| Free-Float |
98.65% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 week | -37.50% | ||
| Current month | -37.50% | ||
| 1 month | +25.00% | ||
| 3 months | -50.00% | ||
| 6 months | -37.50% | ||
| Current year | -80.77% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0 |
| Current year | 0 | | 0.01 |
| 1 year | 0 | | 0.02 |
| 3 years | 0 | | 0.25 |
| 5 years | 0 | | 7.4 |
| 10 years | 0 | | 19.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 61 | 2011-03-31 |
Scott Schaus
CTO | Chief Tech/Sci/R&D Officer | - | 2022-02-28 |
John Waldheim
LAW | General Counsel | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Henry Ji
CHM | Chairman | 61 | 2017-07-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -37.50% | -92.86% | -99.53% | 272K | |
| -6.60% | -8.56% | +49.38% | +63.51% | 65B | |
| -4.09% | -0.11% | +2.22% | +53.15% | 51.19B | |
| +0.03% | +5.56% | +9.10% | +69.05% | 51.2B | |
| -1.53% | +2.70% | +30.48% | +34.12% | 43.93B | |
| -1.34% | +4.12% | +16.64% | +115.13% | 41.96B | |
| -5.97% | -6.22% | +228.95% | +454.22% | 38.14B | |
| +6.53% | +8.02% | +16.40% | +53.41% | 33.24B | |
| -0.90% | -10.49% | +37.09% | -3.70% | 25.2B | |
| -2.76% | -9.54% | -16.58% | -9.19% | 22.03B | |
| Average | -1.66% | -3.17% | +28.08% | +73.02% | 37.19B | |
| Weighted average by Cap. | -2.30% | -1.21% | +42.14% | +95.51% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 52.9M 47.03M 43.59M 39.66M 74.83M 5.02B 76.03M 524M 205M 2.62B 199M 194M 8.35B | 62.84M 55.86M 51.77M 47.1M 88.89M 5.96B 90.31M 622M 244M 3.11B 236M 231M 9.92B |
| Net income | -428M -381M -353M -321M -606M -40.65B -616M -4.24B -1.66B -21.21B -1.61B -1.57B -67.63B | -573M -509M -472M -429M -810M -54.37B -823M -5.67B -2.22B -28.37B -2.15B -2.1B -90.44B |
| Net Debt | 111M 98.4M 91.2M 82.98M 157M 10.51B 159M 1.1B 430M 5.48B 415M 407M 17.48B | 84.53M 75.14M 69.64M 63.36M 120M 8.02B 121M 837M 328M 4.19B 317M 310M 13.35B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-16 | US$0.000500 | 0.00% | 29,020 |
| 26-10-15 | US$0.000500 | +150.00% | 51,244 |
| 26-10-14 | US$0.000200 | -33.33% | 46,016 |
| 26-10-13 | US$0.000300 | -50.00% | 19,896 |
| 26-10-12 | US$0.000600 | -25.00% | 149,142 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- SRNE Stock
Select your edition
All financial news and data tailored to specific country editions
